drugset / Trial / NCT06828393
A Phase 1 Study of S-1117
RandomizedParallel-groupDouble-blindTreatment
Summary
This is the first-in-human study of S-1117 designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers.
Timeline
- Start
- 2025-03
- Primary completion
- 2026-03
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-1117 | Unknown | — | Subcutaneous |
Indications
No indication recorded.